US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares MSCI Emerging Markets ex China ETF

97.23

-0.8200-0.84%

Post-market: 97.500.2700+0.28%19:30 EDT

Volume:1.84M

Turnover:178.74M

Market Cap:25.36B

PE:- -

High:97.26

Open:96.40

Low:96.33

Close:98.05

52wk High:107.12

52wk Low:67.83

Shares:260.80M

Float Shares:260.80M

Volume Ratio:0.95

T/O Rate:0.71%

Dividend:1.92

Dividend Rate:1.98%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Could Samsung Wallet Passport Integration Alter The Investment Case For Clear Secure (YOU)?

Simply Wall St.

Samsung hikes prices for Galaxy A series phones in U.S., Android Authority says

Samsung Prices HBM4 at Triple HBM3E Rate, Betting on AI Compute Arms Race to Redefine Pricing Power

Update: Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates

MT Newswires Live

Samsung Said to Triple HBM Prices Next Year

Samsung Bioepis Signs Partnership Agreement with Teva for Two Biosimilar Candidates

MT Newswires Live

iQOO16 Launches: World's First 2K 165Hz Samsung Summit Screen, Starting at 5,499 Yuan with National Subsidy

Samsung Bioepis Partners with Teva for Two Biosimilar Candidates

MT Newswires Live

Samsung Biologics Signs KRW93.5 Billion CMO Deal with EU Pharmaceutical Firm

MT Newswires Live

Samsung Heavy Industries Secures KRW672.2 Billion Contract for Two LNG Carriers

MT Newswires Live

Samsung Fire & Marine Says Decision to Acquire British Non-Life Insurer Not Finalized

MT Newswires Live

SK hynix Still Undecided on Solidigm Listing

MT Newswires Live

Samsung Fire & Marine Insurance Denies Decision on Reported U.K., U.S. Acquisitions

PolyPeptide Calls Extraordinary Meeting on Samsung Biologics Tender Offer

Samsung Raises Galaxy S26 Prices by Up to $200 as Memory Chip Shortage Drags On

Samsung Biologics Confirms Initial Issue Price for Capital Increase

MT Newswires Live

Goldman Sachs: Samsung's 3Q26 Operating Profit and 2027 HBM Revenue Both Poised to Surpass 100 Trillion Won, Reiterates "Buy" Rating

Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates

MT Newswires Live

Samsung Biologics Discloses Initial Issue Price for Capital Increase

MT Newswires Live

Oil Price and Bond Yield Pressures Push Indian Stock Market to Six-Month Low

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/EMXC/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMXC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMXC\",,,,,undefined,":{"symbol":"EMXC","market":"US","secType":"STK","nameCN":"iShares MSCI Emerging Markets ex China ETF","latestPrice":97.23,"timestamp":1791921600000,"preClose":98.05,"halted":0,"volume":1843493,"hourTrading":{"tag":"盘后","latestPrice":97.5,"preClose":97.23,"latestTime":"19:30 EDT","volume":29700,"amount":2887761.97,"timestamp":1791934204956,"change":0.27,"changeRate":0.002777,"amplitude":0.002777},"delay":0,"changeRate":-0.0083630800611932,"floatShares":260799999,"shares":260799999,"eps":0,"marketStatus":"Not Yet Opened","change":-0.82,"latestTime":"10-13 16:00:00 EDT","open":96.4,"high":97.26,"low":96.33,"amount":178743753.96504,"amplitude":0.009485,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791964800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":98.05,"sharesOutstanding":207100000,"nav":97.714868,"aum":25552437982,"dividendRate":0.019757,"bidAskSpread":0.000131,"preHourTrading":{"tag":"盘前","latestPrice":96.72,"preClose":98.05,"latestTime":"09:26 EDT","volume":225,"amount":21824.0415,"timestamp":1791897989508,"change":-1.33,"changeRate":-0.013565,"amplitude":0.024273},"postHourTrading":{"tag":"盘后","latestPrice":97.5,"preClose":97.23,"latestTime":"19:30 EDT","volume":29700,"amount":2887761.97,"timestamp":1791934204956,"change":0.27,"changeRate":0.002777,"amplitude":0.002777},"volumeRatio":0.954722,"impliedVol":0.2615,"impliedVolPercentile":0.5857},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMXC\",,,,,undefined,":{"symbol":"EMXC","floatShares":260799999,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.954722,"shares":260799999,"dividePrice":1.921,"high":97.26,"amplitude":0.009485,"preClose":98.05,"low":96.33,"week52Low":67.83,"pbRate":"--","week52High":107.12,"institutionHeld":0,"latestPrice":97.23,"eps":0,"divideRate":0.019757,"volume":1843493,"delay":0,"ttmEps":0,"open":96.4,"prevYearClose":72.68,"prevWeekClose":99.02,"prevMonthClose":99.08,"prevQuarterClose":99.08,"fiveDayClose":101.89,"twentyDayClose":96.96,"sixtyDayClose":91.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMXC\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"EMXC","amount":0.588008,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares MSCI Emerging Markets ex China ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"EMXC","amount":1.335744,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares MSCI Emerging Markets ex China ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"EMXC","amount":0.711404,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares MSCI Emerging Markets ex China ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"EMXC","amount":0.99991,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares MSCI Emerging Markets ex China ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"EMXC","amount":0.49101,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares MSCI Emerging Markets ex China ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMXC\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-25","value":0.312384,"currency":"USD"},{"executeDate":"2018-12-18","recordDate":"2018-12-19","paymentDate":"2018-12-24","value":0.88935,"currency":"USD"},{"executeDate":"2019-06-17","recordDate":"2019-06-18","paymentDate":"2019-06-21","value":0.239146,"currency":"USD"},{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.94288,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.228944,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMXC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMXC\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672740003","title":"Could Samsung Wallet Passport Integration Alter The Investment Case For Clear Secure (YOU)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672740003","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672740003?lang=en_us&edition=fundamental","pubTime":"2026-10-03 14:19","pubTimestamp":1791008367,"startTime":"0","endTime":"0","summary":"Clear Secure announced a collaboration with Samsung Electronics America to build Samsung ID with CLEAR, integrating US passports into Samsung Wallet for streamlined identity verification.\nThis move pushes Clear Secure further into everyday digital ID use beyond airports, tying its verification platform directly into Samsung’s mobile ecosystem.\nWe will now look at how Clear Secure’s Samsung Wallet passport integration could influence its investment narrative and potential strategic...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/8041000-choice2-card/1788941901517","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/8041000-choice2-card/1788941901517"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-you/clear-secure/news/could-samsung-wallet-passport-integration-alter-the-investme","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-you/clear-secure/news/could-samsung-wallet-passport-integration-alter-the-investme","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","IEMG","BK4585","BK4504","BK4023","BK4550","BK4539","EMXC","YOU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672074316","title":"Samsung hikes prices for Galaxy A series phones in U.S., Android Authority says","url":"https://stock-news.laohu8.com/highlight/detail?id=2672074316","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672074316?lang=en_us&edition=fundamental","pubTime":"2026-10-03 00:20","pubTimestamp":1790958011,"startTime":"0","endTime":"0","summary":"Samsung (SSNLF) has raised prices for several Galaxy A series phones in the U.S., with the A57 5G now starting at $599.99 from $549.99, the A37 5G ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/samsung-hikes-prices-for-galaxy-a-series-phones-in-u-s-android-authority-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/samsung-hikes-prices-for-galaxy-a-series-phones-in-u-s-android-authority-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4170","BK4588","BK4550","07347","BK4585","EMXC","BK4543","07747","BK4581","BK4504","IEMG","SSNLF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174931784","title":"Samsung Prices HBM4 at Triple HBM3E Rate, Betting on AI Compute Arms Race to Redefine Pricing Power","url":"https://stock-news.laohu8.com/highlight/detail?id=1174931784","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174931784?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:35","pubTimestamp":1790944500,"startTime":"0","endTime":"0","summary":"Samsung Electronics is pushing back to the front lines of the high-bandwidth memory market with an aggressive pricing strategy.On October 2, according to South Korean financial media Maeil Business...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IYK","EMXC","BK4588","WISE","BK4585","AIO","WDAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672719237","title":"Update: Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2672719237","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672719237?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:27","pubTimestamp":1790940462,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  has entered into an agreement with Samsung Bioepis for the global licensing, development, and commercialization of up to six potential biosimilar candidates, the companies said Thursday.Under the deal, South Korea's Samsung Bioepis will manage the development, regulatory registration, and making of the biosimilars. Meanwhile, Teva will be in charge of commercialization in global markets, including the US, Europe, and Canada, with an option to expand to other territories, they said.The companies have confirmed two investigational biosimilar candidates, SB41, referencing Fasenra, and SB44, referencing Ilaris, the companies added.Samsung Bioepis said the parties agreed to keep the total value of the contract confidential, with the deal amount equal to or exceeding the lesser of 2.5% of Samsung Bioepis' 2025 equity or revenue","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4550","BK4504","EMXC","BK4596","LU2324357040.USD","BK4007","BK4588","IEMG","BK4585","BK4559","TEVA","BK4581","LU1983299246.USD","BK4566","BK4557","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127995601","title":"Samsung Said to Triple HBM Prices Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1127995601","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127995601?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:24","pubTimestamp":1790940254,"startTime":"0","endTime":"0","summary":"Reports say Samsung will raise HBM prices threefold next year.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRAM","HBMX","BK4585","BK4588","DRMY","RAM","DISK","MUZ","MUU","MUYY","EMXC","MULL","RAMZ","MUG","DRAL","MUD","MIC","DRMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672716748","title":"Samsung Bioepis Signs Partnership Agreement with Teva for Two Biosimilar Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2672716748","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672716748?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:54","pubTimestamp":1790938459,"startTime":"0","endTime":"0","summary":"Samsung Bioepis  has signed an early-stage partnership with Teva Pharmaceuticals to research, develop, and commercialize two biosimilar candidates, according to a bourse filing on Friday.The two biosimilars drugs - copies of existing biologic medicines - are SB41 for severe eosinophilic asthma and SB44 for hereditary periodic fever syndromes.Under the agreement, Samsung Bioepis will handle development, manufacturing, and supply, while Teva will commercialize the products in the United States, Europe, and Canada.Teva has also secured options to expand territories and enter additional partnerships covering Samsung Bioepis' biosimilar pipeline.The agreement is conditional, with revenue recognition dependent on clinical trial success and product approval, and terminable in the event of regulatory clinical holds or failure to obtain marketing approval.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IEMG","BK4585","BK4504","BK4550","EMXC","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183845422","title":"iQOO16 Launches: World's First 2K 165Hz Samsung Summit Screen, Starting at 5,499 Yuan with National Subsidy","url":"https://stock-news.laohu8.com/highlight/detail?id=1183845422","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183845422?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:50","pubTimestamp":1790938243,"startTime":"0","endTime":"0","summary":"iQOO16 has been officially unveiled, arriving in three color options: Light Chaser, Legend, and Track.Four versions are available, with a starting price of 5,499 yuan after national subsidies. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","EMXC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672425716","title":"Samsung Bioepis Partners with Teva for Two Biosimilar Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2672425716","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672425716?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:46","pubTimestamp":1790937960,"startTime":"0","endTime":"0","summary":"Samsung Bioepis  has signed an early-stage partnership with Teva Pharmaceuticals International to research, develop, and commercialize two biosimilar candidates, according to a Korean bourse filing on Friday.The two biosimilars, copies of existing biologic medicines, are SB41 for severe eosinophilic asthma and SB44 for hereditary periodic fever syndromes.Under the agreement, Samsung Bioepis will handle development, manufacturing, and supply, while Teva will market the products in the U.S., Europe, and Canada.Teva has also secured options to expand territories and enter additional partnerships covering Samsung Bioepis' biosimilar pipeline.The agreement is conditional, with revenue recognition dependent on clinical trial success and product approval, and terminable in the event of regulatory clinical holds or failure to obtain marketing approval.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IEMG","BK4585","BK4504","BK4550","EMXC","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672171874","title":"Samsung Biologics Signs KRW93.5 Billion CMO Deal with EU Pharmaceutical Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2672171874","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672171874?lang=en_us&edition=fundamental","pubTime":"2026-10-02 16:54","pubTimestamp":1790931256,"startTime":"0","endTime":"0","summary":"Samsung Biologics  has entered into a 93.5 billion won biologics CMO sales or supply contract with an unnamed EU-based pharmaceutical company, according to a bourse filing on Friday.The contract period runs from Oct. 2, 2026, to Dec. 31, 2031, with no deposit or advance payment required, and the disclosed amount is based on a committed binding amount of $68.8 million at an exchange rate of 1,359.60.The filing said the contracting party's identity will remain undisclosed until Dec. 31, 2031, due to business confidentiality, and the contract period may be adjusted by mutual agreement.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4504","IEMG","BK4581","BK4550","BK4585","EMXC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672943777","title":"Samsung Heavy Industries Secures KRW672.2 Billion Contract for Two LNG Carriers","url":"https://stock-news.laohu8.com/highlight/detail?id=2672943777","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672943777?lang=en_us&edition=fundamental","pubTime":"2026-10-02 13:27","pubTimestamp":1790918859,"startTime":"0","endTime":"0","summary":"Samsung Heavy Industries  secured a 672.2 billion won contract to build two liquefied natural gas carriers for an unnamed Asian buyer, according to a filing with the Korean bourse on Friday.The contract is valid till May 31, 2029. Payment will be made as construction progresses, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","PBOG","VDE","ERX","BK4550","BK4504","IEMG","EMXC","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672799493","title":"Samsung Fire & Marine Says Decision to Acquire British Non-Life Insurer Not Finalized","url":"https://stock-news.laohu8.com/highlight/detail?id=2672799493","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672799493?lang=en_us&edition=fundamental","pubTime":"2026-10-02 11:55","pubTimestamp":1790913310,"startTime":"0","endTime":"0","summary":"Samsung Fire & Marine Insurance  said it has not made any specific decision to acquire a major British non-life insurer, denying media reports that the company and its affiliate Samsung Life Insurance  were seeking to acquire UK- and US-based insurers.The company said it is pursuing global business expansion to secure new growth engines and will make another disclosure when specific details are finalized.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MARPS","EMXC","BK4585","BK4504","BK4213","IEMG","BK4550","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672796366","title":"SK hynix Still Undecided on Solidigm Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2672796366","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672796366?lang=en_us&edition=fundamental","pubTime":"2026-10-02 10:22","pubTimestamp":1790907775,"startTime":"0","endTime":"0","summary":"SK hynix's  U.S.-based NAND flash subsidiary Solidigm's potential listing in the U.S. is still undecided, the chipmaker said in a Thursday release.The South Korean firm said it was reviewing several options to boost Solidigm's competitiveness, including investment and capital allocation, while considering its overall investment plans, financial position, and shareholder value, it said.Solidigm was launched during SK Hynix's acquisition of Intel's NAND and solid-state drive  businesses.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4141","SKHU","SKHQ","MIC","SKHA","EMXC","MUU","SKHN","LU0823413660.USD","SKUU","RAM","SKHYV","RAMZ","SKHZ","SKDD","BK4588","LU0823413587.USD","LU0106261612.USD","SK","SKHX","LU1815336091.USD","LU0012050646.USD","BK4585","MUD","MUZ","HYNX","DRAL","LU0823397103.USD","LU0274383776.USD","03516","MUG","DRMY","SKHL","MUYY","SKHY","LU1956131251.USD","07709","LU0823397285.USD","EEMO","SSD","DISK","LU0757428866.USD","DRAM","LU0053671581.USD","BK4086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672255795","title":"Samsung Fire & Marine Insurance Denies Decision on Reported U.K., U.S. Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2672255795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672255795?lang=en_us&edition=fundamental","pubTime":"2026-10-02 09:42","pubTimestamp":1790905361,"startTime":"0","endTime":"0","summary":"Samsung Fire & Marine Insurance Co., Ltd ( ($KR:000810) ) has shared an update. Samsung Fire & Marine Insurance has addressed market rumors that it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/samsung-fire-marine-insurance-denies-decision-on-reported-u-k-u-s-acquisitions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/samsung-fire-marine-insurance-denies-decision-on-reported-u-k-u-s-acquisitions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IEMG","MARPS","BK4213","BK4504","BK4585","BK4581","EMXC","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672793580","title":"PolyPeptide Calls Extraordinary Meeting on Samsung Biologics Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672793580","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672793580?lang=en_us&edition=fundamental","pubTime":"2026-10-02 08:32","pubTimestamp":1790901154,"startTime":"0","endTime":"0","summary":"PolyPeptide Group AG ( ($CH:PPGN) ) has issued an update. PolyPeptide Group AG, a global CDMO specializing in peptide-based active pharmaceutical i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/polypeptide-calls-extraordinary-meeting-on-samsung-biologics-tender-offer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/polypeptide-calls-extraordinary-meeting-on-samsung-biologics-tender-offer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEMG","BK4581","BK4550","BK4585","LNGR","EMXC","BK4588","IEIH","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180417076","title":"Samsung Raises Galaxy S26 Prices by Up to $200 as Memory Chip Shortage Drags On","url":"https://stock-news.laohu8.com/highlight/detail?id=1180417076","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180417076?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:12","pubTimestamp":1790871136,"startTime":"0","endTime":"0","summary":"Samsung Electronics has followed in the footsteps of Apple and Google, lifting the price of its flagship phones by $100 to $200, passing more of the memory cost burden onto consumers.Samsung...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMXC","CARU","UUP","BK4585","UDN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672751637","title":"Samsung Biologics Confirms Initial Issue Price for Capital Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2672751637","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672751637?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:10","pubTimestamp":1790853033,"startTime":"0","endTime":"0","summary":"Samsung Biologics  said it has confirmed the initial offering price of its 2.7 trillion won offering after finalizing the initial issue price of 2.3 million shares, according to a Thursday filing with the Korea Exchange.The company said the total offering price was revised down from 3.001 trillion won previously stated in the registration statement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","BK4550","BK4588","BK4585","EMXC","BK4504","IEMG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101891476","title":"Goldman Sachs: Samsung's 3Q26 Operating Profit and 2027 HBM Revenue Both Poised to Surpass 100 Trillion Won, Reiterates \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1101891476","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101891476?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:41","pubTimestamp":1790851313,"startTime":"0","endTime":"0","summary":"Goldman Sachs has released its latest research report, reiterating a \"Buy\" rating on Samsung Electronics. The firm believes Samsung Electronics' fundamentals remain solid, with memory demand...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MUU","RAM","LU0345770308.USD","LU2237438978.USD","LU1791807156.HKD","BK4516","HBMX","LU1804176565.USD","LU2471134879.HKD","DISK","LU2237443895.HKD","LU2471134523.USD","DRAL","LU0251131958.USD","LU2237443622.USD","DRMP","DRMY","MUG","LU1868836591.USD","MUD","LU0096364046.USD","LU0251142724.SGD","EMXC","RAMZ","LU1868836914.USD","LU0345770993.USD","IE0004091025.USD","LU2237443382.USD","IE0034235188.USD","LU0048573561.USD","LU2237443549.SGD","LU2471134952.CNY","MUYY","LU1144417596.USD","LU1868837136.USD","LU2896262040.SGD","BK4550","LU1868837300.USD","DRAM","MIC","MULL","IE00B19Z3B42.SGD","LU2237443978.SGD","LU2750360997.AUD","LU0210536198.USD","MUZ","LU1894683264.USD","LU2265009873.SGD","GSX","LU0106831901.USD","BK4588","IE00BSNM7G36.USD","LU0868494708.USD","LU0942090050.USD","LU2237443465.HKD","LU2750360641.GBP","IE00BFXG1179.USD","LU0061475181.USD","IE00B19Z3581.USD","LU0742534661.SGD","LU1868836757.USD","IE0004086264.USD","LU1894683348.USD","GS","BK4533","BK4127","BK4552","LU2471134796.USD","BK4585","LU0868494617.USD","LU1668664300.SGD","IE0002270589.USD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672919755","title":"Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2672919755","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672919755?lang=en_us&edition=fundamental","pubTime":"2026-10-01 17:30","pubTimestamp":1790847036,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  has entered into an agreement with Samsung Bioepis for the global licensing, development, and commercialization of up to six potential biosimilar candidates, the companies said on Thursday.Under the deal, South Korea's Samsung Bioepis will manage the development, regulatory registration, and making of the biosimilars. Meanwhile, Teva will be in charge of commercialization in global markets, including the US, Europe, and Canada, with an option to expand to other territories, Teva said.The companies have confirmed two investigational biosimilar candidates, SB41, referencing Fasenra and SB44, referencing Ilaris, it added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMXC","BK4596","BK4504","BK4581","LU1983299246.USD","BK4557","BK4584","BK4588","TEVA","BK4559","BK4550","IEMG","LU2324357040.USD","BK4007","BK4585","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672753340","title":"Samsung Biologics Discloses Initial Issue Price for Capital Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2672753340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672753340?lang=en_us&edition=fundamental","pubTime":"2026-10-01 16:34","pubTimestamp":1790843641,"startTime":"0","endTime":"0","summary":"Samsung Biologics (KRX:207940) said the preliminary issue price for its capital increase will be nearly 1.2 million won per share.The final issue price is scheduled to be released Nov. 5, a Thursday bourse filing showed.The capital increase was first announced in August.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4550","BK4504","EMXC","BK4588","IEMG","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130126273","title":"Oil Price and Bond Yield Pressures Push Indian Stock Market to Six-Month Low","url":"https://stock-news.laohu8.com/highlight/detail?id=1130126273","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130126273?lang=en_us&edition=fundamental","pubTime":"2026-10-01 16:20","pubTimestamp":1790842829,"startTime":"0","endTime":"0","summary":"Indian equities tumbled to their lowest level in six months as rebounding oil prices and surging global bond yields weighed heavily on market sentiment, dragging the National Stock Exchange's Nifty...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERX","SPEM","WEEI","DIG","FEMR","DBE","OILT","INQQ","XXCH","EMES","PEMX","XSOE","XLEX","SCIN","BK4523","BK4550","IXC","TEMR","OILK","BBEM","DBO","ASIA","XC","GUSH","VEU","BK4585","NFTY","XCNY","BK4588","NDIA","VEXC","INDL","EET","USE","SMIN","VOOV","MEM","INDQ","DRIP","EEMA","SPXT","IOPP","EQLT","DUG","EEMV","INDE","XCEM","FLIBF","KEMX","GLIN","PIN","INDZ","OIH","DRLL","PXJ","MEMX","BCHI","BWET","TEMX","IEO","XES","INDY","SCHE","09141","VDE","03141","PEJ","USOI","WTIU","INDA","RWEM","OILU","DFAE","GIND","MFEM","BKF","INCO","INDH","UAE","IND","FLIN","IMVP","BKEM","AVEM","DEXC","TPOR","AEF","RAYE","HEEM","QLVE","BNO","UGA","DBC","PXE","SEEM","QEMM","BK4570","EPI","EMXC","FTXN","STXE","SDOG","TAJX","USL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}